One of the hardest things to do as a medtech founder is stay narrow. Every conversation with a customer surfaces some new idea about what the product could also do, and every conversation with an investor surfaces some new idea about a bigger market you could also address. The pressure to widen is constant.
VynMed's product is narrow on purpose. Here's what it doesn't do, so you know where the edges are.
VynMed is not a diagnostic test. We don't make the strip. We don't change the chemistry. We don't claim clinical performance beyond what the strip manufacturer already claims. The diagnostic value of a VynScan read is inherited directly from the underlying FDA-cleared strip. Our job is to read and report that existing result consistently and quickly.
VynMed is not a lab. We're not processing samples, running reagents, or producing laboratory-derived results. We don't interpret — we capture what the strip itself has already shown. A lab has a different regulatory posture, a different workflow, and a different business model. Ours is simpler on purpose.
VynMed is not trying to replace any existing strip manufacturer. We're downstream of them. The more strip vendors there are, the better for us. Every strip manufacturer who produces a quality cleared product makes VynScan more valuable to its customers. We hope to partner with several strip vendors over time, not compete with them.
VynMed is not an AI diagnostic company. There's computer vision in the reader, yes, but it's narrow purpose-built software that measures line intensity against known reference positions on a known strip geometry. It's not a black-box neural network making clinical interpretations on its own. Every reading can be traced back to specific pixel measurements against specific thresholds. That traceability is important for FDA, for audits, and for us.
Clarity about what you aren't is usually more valuable than claims about what you are. That's true in product design, it's true in positioning, and it's especially true in early-stage fundraising conversations where every founder is tempted to stretch to match what the investor in the room wants to hear.